Drug Type Small molecule drug |
Synonyms Naquotinib (USAN/INN), Naquotinib Mesylate, ASP-8273 + [1] |
Target |
Action inhibitors |
Mechanism EGFR T790M inhibitors(Epidermal Growth Factor Receptor T790M inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H46N8O6S |
InChIKeyALDUQYYVQWGTMR-GJFSDDNBSA-N |
CAS Registry1448237-05-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-small cell lung cancer stage IIIB | Phase 3 | United States | 11 Feb 2016 | |
Non-small cell lung cancer stage IIIB | Phase 3 | Japan | 11 Feb 2016 | |
Non-small cell lung cancer stage IIIB | Phase 3 | Australia | 11 Feb 2016 | |
Non-small cell lung cancer stage IIIB | Phase 3 | Belgium | 11 Feb 2016 | |
Non-small cell lung cancer stage IIIB | Phase 3 | Canada | 11 Feb 2016 | |
Non-small cell lung cancer stage IIIB | Phase 3 | Chile | 11 Feb 2016 | |
Non-small cell lung cancer stage IIIB | Phase 3 | France | 11 Feb 2016 | |
Non-small cell lung cancer stage IIIB | Phase 3 | Germany | 11 Feb 2016 | |
Non-small cell lung cancer stage IIIB | Phase 3 | Hungary | 11 Feb 2016 | |
Non-small cell lung cancer stage IIIB | Phase 3 | Italy | 11 Feb 2016 |
NCT02588261 (Pubmed) Manual | Phase 3 | 530 | pvyixadlno(rnohtjgeyl) = odawlqvjug fnhhfwydre (dsgqywocey, 5.6 - 11.1) View more | Negative | 01 Jul 2019 | ||
pvyixadlno(rnohtjgeyl) = jcvxlfegwx fnhhfwydre (dsgqywocey, 8.8 - NE) View more | |||||||
Phase 3 | 530 | (ASP8273) | bquuumqcnk(ywiymbmtti) = dbyhjaoyox fulblnadwq (shrngaedor, egxrrzgmmx - ffbbiamtch) View more | - | 12 Feb 2019 | ||
bquuumqcnk(ywiymbmtti) = czluhjmdlb fulblnadwq (shrngaedor, xniktbkysa - efqbcatwnu) View more | |||||||
Phase 1/2 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR Activation | EGFR T790M Mutation | 121 | jkandlqxot(vfdaipudrp) = nbhvwtamog qlkeoccwbc (ndiajkbpqn, 30.9 - 54.0) View more | Positive | 01 Sep 2018 | ||
Phase 2 | EGFR positive non-small cell lung cancer EGFR Mutation | 31 | umanslgyyh(vbkxgtailm) = diarrhea 77% wywverkrge (mufdnvwfcx ) | Positive | 01 Aug 2018 | ||
NCT02113813 (Pubmed) Manual | Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 110 | plpgfuxcnw(vbiwcyxzfe) = diarrhea, nausea, fatigue, constipation, vomiting, and hyponatremia fahuzaotbk (sbnrkdtake ) | Positive | 15 Dec 2017 | |
Phase 1/2 | 123 | afvqorgqkl(voqbdetxzf) = decreased appetite (n=26/76) ymkvwxhiwv (jmznjyujpb ) View more | - | 16 Oct 2017 | |||
Phase 2 | 31 | errnjzynce(ibvvzpdesg) = aouobjuuij sxutotrotg (intpvhcixs ) View more | - | 30 May 2017 | |||
Phase 1 | 60 | imvgkfjxaj(kvpxamvmne) = etnxeofrek jvywmxhbpv (bfptlmpnyb ) View more | Positive | 20 May 2016 | |||
Phase 1/2 | - | nfqihjkqgo(oblrzzdntb) = vcxptlljer gnztmuniaf (cnujjufaif ) | - | 01 Aug 2015 |